D
Drugs Made In America Acquisition II Corp.
Period
FY 2025
Revenue
—
Net Income
$4.19M
Total Assets
$504.96M
Equity
$-17.77M
Shares Out
63.70M
Op. Cash Flow
$-1.02M
Business
Drugs Made In America Acquisition II Corp. is a blank-check company formed to effect a merger, share exchange, asset acquisition, or other business combination with one or more businesses. The company completed an initial public offering in September 2025, raising proceeds held in trust. It seeks to identify and acquire pharmaceutical industry targets with focus on domestic manufacturing of critical drugs and active pharmaceutical ingredients.
Summary from 10-K filed 2026-04-15
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 |
|---|---|---|
| General and administrative costs | 488,385 | |
| Total operating expenses | 488,385 | |
| Loss from operations | −488,385 | |
| Interest earned on cash and investments held in Trust Account | 5 | |
| Gain on extinguishment of over-allotment option liability | 553,748 | |
| Provision for credit losses | −812,113 | |
| Total other income | 5 | |
| Net income (loss) | 4 |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2024 2024-08-31 |
|---|---|---|---|---|
| Cash | 223 | 17,035 | — | |
| Due from Sponsor, net of reserve for credit losses of $812,113 | — | — | — | |
| Prepaid expenses | 25,814 | 42,580 | — | |
| Total Current Assets | 26,037 | 59,615 | — | |
| Deferred offering costs | — | 78,449 | — | |
| Cash and investments held in Trust Account | 505 | — | — | |
| Total Non-current Assets | 505 | 78,449 | — | |
| TOTAL ASSETS | 505 | 138,064 | — | |
| Accounts payable | 99,359 | — | — | |
| Accrued expenses | 88,343 | — | — | |
| Accrued offering costs | 113,162 | 4,683 | — | |
| Promissory Note Related Party | — | 250,100 | — | |
| Total Current Liabilities | 300,864 | 254,783 | — | |
| Deferred underwriting fee payable | 18 | — | — | |
| Total Non-current Liabilities | 18 | — | — | |
| TOTAL LIABILITIES | 18 | 254,783 | — | |
| Commitments and Contingencies (Note 6) | — | — | — | |
| Ordinary shares subject to possible redemption, 50,000,000 shares at redemption value of $10.00 and $0 per share as of December 31, 2025 and 2024, respectively | 505 | — | — | |
| Preference shares, $0.0001 par value; 1,000,000 shares authorized; none issued or outstanding as of December 31, 2025 and 2024 | — | — | — | |
| Ordinary shares, $0.0001 par value; 220,000,000 shares authorized; [13,700,000] and 14,375,000 shares issued and outstanding, excluding 50,000,000 and 0 shares subject to redemption as of December 31, 2025 and 2024, respectively(1)(2) | 1,369 | 1,437 | — | |
| Additional paid-in capital | — | 33,563 | — | |
| Accumulated deficit | −18 | −151,719 | — | |
| Total Shareholders Deficit | −18 | −116,719 | — | |
| TOTAL LIABILITIES, ORDINARY SHARES SUBJECT TO POSSIBLE REDEMPTION, AND SHAREHOLDERS DEFICIT | 505 | 138,064 | — |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 |
|---|---|---|
| Payment of operating costs through promissory note | 77,799 | |
| Prepaid expenses | 16,766 | |
| Due from Sponsor | −812,113 | |
| Accounts payable | 99,359 | |
| Accrued expenses | 88,343 | |
| Net cash used in operating activities | −1 | |
| Investment of cash into Trust Account | −500 | |
| Net cash used in investing activities | −500 | |
| Proceeds from sale of Units, net of underwriting discounts paid | 490 | |
| Proceeds from issuance of founder shares to Sponsor | — | |
| Proceeds from promissory note - related party | — | |
| Proceeds from sale of Private Placement Units | 12 | |
| Repayment of promissory note - related party | −533,781 | |
| Payment of offering costs | −464,800 | |
| Net cash provided by financing activities | 501 | |
| Net Change in Cash | −16,812 | |
| Offering costs included in accrued offering costs | 108,479 | |
| Deferred offering costs paid through promissory note related party | 205,881 | |
| Accretion and remeasurement of redeemable ordinary shares to redemption value | 44 | |
| Deferred underwriting fee payable | 18 | |
| Deferred offering costs for issuance of Public Units | 857,609 | |
| Fair value of rights included in Public Units | 10 |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro
Frequently asked questions
What is Drugs Made In America Acquisition II Corp.'s CIK number?
Drugs Made In America Acquisition II Corp.'s SEC CIK number is 0002040475 (2040475). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Drugs Made In America Acquisition II Corp.'s SEC filings?
All of Drugs Made In America Acquisition II Corp.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.